Do analysts recommend AIMD or ALZN?

Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,021.21%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is AIMD or ALZN more profitable?

Alzamend Neuro has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Ainos -11,912.10% -160.55% -62.29% Alzamend Neuro N/A -177.52% -140.41%

Which has higher earnings & valuation, ALZN or CMMB?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.22 N/A

Is ALZN or CMMB more profitable?

Chemomab Therapeutics' return on equity of -89.03% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Chemomab Therapeutics N/A -89.03% -79.68%

Do analysts recommend TPST or ALZN?

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,021.21%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, TPST or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A

Is TPST or ALZN more profitable?

Alzamend Neuro's return on equity of -177.52% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% Alzamend Neuro N/A -177.52% -140.41%

Which has better earnings and valuation, ALZN or CTXR?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Citius Pharmaceuticals N/A N/A -$37.43M -$2.13 N/A

Is ALZN or CTXR more profitable?

Citius Pharmaceuticals' return on equity of -61.09% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Citius Pharmaceuticals N/A -61.09% -35.36%

Which has better earnings & valuation, QNCX or ALZN?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A

Is QNCX or ALZN more profitable?

Quince Therapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A N/A -67.99% Alzamend Neuro N/A -177.52% -140.41%

Alzamend Neuro (ALZN) Competitors

$1.32 +0.06 (+4.76%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 +0.02 (+1.52%)

As of 04:42 PM Eastern

Compare

ALZN vs. AIMD, CMMB, TPST, CTXR, and QNCX

Should you buy Alzamend Neuro stock or one of its competitors? MarketBeat compares Alzamend Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alzamend Neuro include Ainos (AIMD), Chemomab Therapeutics (CMMB), Tempest Therapeutics (TPST), Citius Pharmaceuticals (CTXR), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry.

How does Alzamend Neuro compare to Ainos?

Ainos (NASDAQ:AIMD) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Ainos has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market.

Alzamend Neuro has a consensus target price of $28.00, indicating a potential upside of 2,021.21%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alzamend Neuro has lower revenue, but higher earnings than Ainos. Alzamend Neuro is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	110.76	-$14.77M	-$2.89	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

In the previous week, Ainos' average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
Ainos	Neutral
Alzamend Neuro	Neutral

Alzamend Neuro has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Ainos' return on equity of -160.55% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Alzamend Neuro	N/A	-177.52%	-140.41%

49.6% of Alzamend Neuro shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 1.4% of Alzamend Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Alzamend Neuro beats Ainos on 7 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Chemomab Therapeutics?

Alzamend Neuro (NASDAQ:ALZN) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Alzamend Neuro's average media sentiment score of 0.00 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Chemomab Therapeutics	Neutral

Alzamend Neuro currently has a consensus target price of $28.00, indicating a potential upside of 2,021.21%. Chemomab Therapeutics has a consensus target price of $25.00, indicating a potential upside of 1,600.68%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.22	N/A

Chemomab Therapeutics' return on equity of -89.03% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Chemomab Therapeutics	N/A	-89.03%	-79.68%

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Alzamend Neuro has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market.

Summary

Alzamend Neuro beats Chemomab Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Alzamend Neuro compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

Tempest Therapeutics has a beta of -1.73, meaning that its stock price is 273% less volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.14, meaning that its stock price is 86% less volatile than the broader market.

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 36.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alzamend Neuro's return on equity of -177.52% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
Alzamend Neuro	N/A	-177.52%	-140.41%

Alzamend Neuro is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Alzamend Neuro has a consensus price target of $28.00, suggesting a potential upside of 2,021.21%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tempest Therapeutics had 5 more articles in the media than Alzamend Neuro. MarketBeat recorded 5 mentions for Tempest Therapeutics and 0 mentions for Alzamend Neuro. Tempest Therapeutics' average media sentiment score of 0.80 beat Alzamend Neuro's score of 0.00 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Positive
Alzamend Neuro	Neutral

Summary

Alzamend Neuro beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Citius Pharmaceuticals?

Alzamend Neuro (NASDAQ:ALZN) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Alzamend Neuro currently has a consensus target price of $28.00, suggesting a potential upside of 2,021.21%. Citius Pharmaceuticals has a consensus target price of $5.00, suggesting a potential upside of 816.59%. Given Alzamend Neuro's higher probable upside, equities analysts plainly believe Alzamend Neuro is more favorable than Citius Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Citius Pharmaceuticals' return on equity of -61.09% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Citius Pharmaceuticals	N/A	-61.09%	-35.36%

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A

Alzamend Neuro has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 1 mentions for Citius Pharmaceuticals and 0 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 0.00 equaled Citius Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Neutral
Citius Pharmaceuticals	Neutral

Summary

Citius Pharmaceuticals beats Alzamend Neuro on 9 of the 12 factors compared between the two stocks.

How does Alzamend Neuro compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Quince Therapeutics currently has a consensus price target of $690.00, indicating a potential upside of 3,574.12%. Alzamend Neuro has a consensus price target of $28.00, indicating a potential upside of 2,021.21%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Quince Therapeutics is more favorable than Alzamend Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quince Therapeutics' average media sentiment score of 0.00 equaled Alzamend Neuro'saverage media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Neutral
Alzamend Neuro	Neutral

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by insiders. Comparatively, 1.4% of Alzamend Neuro shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A

Quince Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Alzamend Neuro has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market.

Quince Therapeutics' return on equity of 0.00% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	N/A	-67.99%
Alzamend Neuro	N/A	-177.52%	-140.41%

Summary

Quince Therapeutics beats Alzamend Neuro on 9 of the 12 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.02M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-0.61	20.80	27.00	24.20
Price / Sales	N/A	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	0.27	8.17	10.67	6.26
Net Income	-$4.51M	$23.81M	$3.60B	$331.76M
7 Day Performance	9.09%	-1.12%	-0.32%	-1.10%
1 Month Performance	8.20%	2.64%	1.88%	-1.26%
1 Year Performance	-59.51%	45.50%	25.50%	18.84%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	1.927 of 5 stars	$1.32 +4.8%	$28.00 +2,021.2%	-61.6%	$5.02M	N/A	N/A	4	Upcoming Earnings Gap Down
AIMD Ainos	0.7741 of 5 stars	$1.88 -7.8%	N/A	-42.6%	$17.39M	$120K	N/A	40	News Coverage Positive News Gap Up
CMMB Chemomab Therapeutics	1.8252 of 5 stars	$2.77 +15.4%	$25.00 +802.5%	-66.8%	$17.28M	N/A	N/A	20	High Trading Volume
TPST Tempest Therapeutics	1.4676 of 5 stars	$0.99 -7.4%	N/A	-84.9%	$17.10M	N/A	N/A	20	News Coverage
CTXR Citius Pharmaceuticals	1.9087 of 5 stars	$0.58 -4.0%	$5.00 +756.9%	-68.6%	$16.68M	N/A	N/A	20	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. AIMD, CMMB, TPST, CTXR, and QNCX

How does Alzamend Neuro compare to Ainos?

Summary

How does Alzamend Neuro compare to Chemomab Therapeutics?

Summary

How does Alzamend Neuro compare to Tempest Therapeutics?

Summary

How does Alzamend Neuro compare to Citius Pharmaceuticals?

Summary

How does Alzamend Neuro compare to Quince Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. AIMD, CMMB, TPST, CTXR, and QNCX

How does Alzamend Neuro compare to Ainos?

Which has more risk and volatility, AIMD or ALZN?

Do analysts recommend AIMD or ALZN?

Which has better valuation & earnings, AIMD or ALZN?

Does the media favor AIMD or ALZN?

Is AIMD or ALZN more profitable?

Do institutionals & insiders believe in AIMD or ALZN?

Summary

How does Alzamend Neuro compare to Chemomab Therapeutics?

Does the media prefer ALZN or CMMB?

Do analysts rate ALZN or CMMB?

Which has higher earnings & valuation, ALZN or CMMB?

Is ALZN or CMMB more profitable?

Do insiders & institutionals believe in ALZN or CMMB?

Which has more risk & volatility, ALZN or CMMB?

Summary

How does Alzamend Neuro compare to Tempest Therapeutics?

Which has more volatility and risk, TPST or ALZN?

Do insiders & institutionals hold more shares of TPST or ALZN?

Is TPST or ALZN more profitable?

Which has better earnings & valuation, TPST or ALZN?

Do analysts recommend TPST or ALZN?

Does the media prefer TPST or ALZN?

Summary

How does Alzamend Neuro compare to Citius Pharmaceuticals?

Do analysts rate ALZN or CTXR?

Is ALZN or CTXR more profitable?

Do insiders & institutionals hold more shares of ALZN or CTXR?

Which has better earnings and valuation, ALZN or CTXR?

Which has more volatility & risk, ALZN or CTXR?

Does the media refer more to ALZN or CTXR?

Summary

How does Alzamend Neuro compare to Quince Therapeutics?

Do analysts prefer QNCX or ALZN?

Does the media prefer QNCX or ALZN?

Do institutionals and insiders believe in QNCX or ALZN?

Which has better earnings & valuation, QNCX or ALZN?

Which has more volatility and risk, QNCX or ALZN?

Is QNCX or ALZN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools